Relationships between clinical measures of visual function and anatomic changes associated with bevacizumab treatment for choroidal neovascularization in age-related macular degeneration

Eye

Volumn 23, Issue 2, 2009, Pages 453-460

  Unver Y B ^a   Yavuz, G A ^b   Bekiroglu N ^c   Presti, P ^d   Li, W ^e   Sinclair, S H ^e,f  

^a UHS Beyoglu Eye Training and Research Hospital   (Turkey)

^b DUZCE UNIVERSITY   (Turkey)

^c MARMARA UNIVERSITY   (Turkey)

^d GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^e DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^f Vimetrics LLC   (United States)

Author keywords

Age related macular degeneration; Anatomic outcome; Avastin treatment; Bevacizumab; Central field acuity testing; Vision outcome

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; ATROPHY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTINGENT NEGATIVE VARIATION; EYE FIXATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; MALE; OCULAR FIBROSIS; OPTICAL COHERENCE TOMOGRAPHY; PERIMETRY; PILOT STUDY; RETINA DETACHMENT; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; TREATMENT OUTCOME; VISION; CHOROIDAL NEOVASCULARIZATION; COMPLICATION; DRUG ADMINISTRATION; DRUG EFFECTS; EPIDEMIOLOGY; FIBROSIS; MACULAR DEGENERATION; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PIGMENT EPITHELIUM; PROCEDURES; VERY ELDERLY; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; DRUG ADMINISTRATION SCHEDULE; EPIDEMIOLOGIC METHODS; FEMALE; FIBROSIS; HUMANS; MACULAR DEGENERATION; MALE; MIDDLE AGED; RETINAL PIGMENT EPITHELIUM; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL FIELD TESTS;

EID: 60149098855     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2008.349     Document Type: Article

References (34)

1. Klein R, Klein BE, Jensen SC, Meuer SM. The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 1997; 104: 7-21.
2. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular dejeneration. Ophthalmology 2006; 113: 363-372.
3. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular dejeneration. Am J Ophthalmol 2006; 142: 1-9.
4. Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 2007; 27: 133-140.
5. Krebs I, Binder S, Stolba U, Schmid K, Glittenberg C, Brannath W et al. Optical coherence tomography guided retreatment of photodynamic therapy. Br J Ophthalmol 2005; 89: 1184-1187.
6. Sahni J, Stanga P, Wong D, Harding S. Optical coherence tomography in photodynamic therapy for subfoveal choroidal neovascularisation secondary to age related macular degeneration: a cross sectional study. Br J Ophthalmol 2005; 89: 316-320.
7. Moutary T, Alarbi M, Mahon G, Stevenson M, Chakravarthy U. Relationships between clinical measures of visual function, fluorescein angiographic and optical coherence tomography features in patients with subfoveal choroidal neovascularization. Br.J. Ophthalmol 2008; 92: 361-364.
8. Hee MR, Baumal CR, Puliafito CA, Duker JS, Reichel E, Wilkins JR et al. Optical coherence tomography of age-related macular degeneration and choroidal neovascularization. Ophthalmology 1996; 10: 1260-1270.
9. Chen CY, Wong JY, Heriot WJ et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. Am J Ophthalmol 2007; 143: 510-512.
10. Yoganathan P, Deramo VA, Lai JC, Tibrewala RK, Fastenberg DM. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina 2006; 26: 994-998.
11. Salinas-Alaman A, Garcia-Layana A, Maldonado MJ, Sainz-Gómez C, Alvárez-Vidal A. Using optical coherence tomography to monitor photodynamic therapy in age-related macular degeneration. Am J Ophthalmol 2005; 140: 23-28.
12. Ting TD, Oh M, Cox TA, Meyer CH, Toth CA. Decreased visual acuity associated with cystoid macular edema in neovascular age-related macular degeneration. Arch Ophthalmol 2002; 120: 731-737.
13. Sinclair SH, Alaniz R, Presti P. Laser treatment of diabetic macular edema: comparison of ETDRS-level treatment with threshold-level treatment by using high-contrast discriminant central visual field testing. Semin Ophthalmol 1999; 14(4): 214-222.
14. Ferris III FL, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol 1982; 94: 91-96.
15. Hee MR, Izatt JA, Swanson EA, Huang D, Schuman JS, Lin CP et al. Optical coherence tomography of the human retina. Arch Ophthalmol 1995; 113: 325-332.
16. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 1997; 81: 154-162.
17. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 2004; 122: 598-614.
18. Kliffen M, Van der Schaft T, Mooy CM, De Jong PT. Morphologic changes in age-related maculopathy. Microsc Res Tech 1997; 36: 106-122.
19. Gonzalez E, Tarita-Nistor L, Markowitz SN, Steinbach MJ. Computer-based test to measure optimal visual acuity in age-related macular degeneration. Invest Ophthalmol Visl Sci 2007; 48: 4838-4845.
20. Moore T. Shape representations and visual guidance of saccadic eye movements. Science 1999; 285: 5435.
21. Hoffman JE. The role of attention in saccadic eye movements. Percept Psychophys 1995; 5: 787-795.
22. Vogel GL. Saccadic eye movements: theory testing and therapy. J Behav Optom 1995; 6(1): 3-12.
23. Sunness J, Applegate C, Haselwood D, Rubin GS. Fixation patterns and rading rates in eyes with central scotomas from advanced atrophic age-related macular degeneration and Stargardt disease. Ophthalmology 1996; 103: 1458-1466.
24. Sunness J, Applegate C. Long-term follow-up of fixation patterns in eyes with central scotomas from geographic trophy that is associated with age-related macular degeration. Am J Ophthalmol 2005; 140: 1085-1093.
25. Spaide RF, Laud K, Fine HF, Klancnik Jr JM, Meyerle CB, Yannuzzi LA et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006; 26: 383-390.
26. Aggio FB, Farah ME, Silva WC, Melo GB. Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments. Graefes Arch Clin Exp Ophthalmol 2007; 245: 215-220.
27. Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn Jr HW et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006; 26: 495-511.
28. Emerson MV, Lauer AK, Flaxel CJ, Wilson DJ, Francis PJ, Stout JT et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 2007; 27: 439-444.
29. Lazic R, Gabric N. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007; 245: 68-73.
30. Pedersen R, Soliman W, Lund-Andersen H, Larsen M. Treatment of choroidal neovascularization using intravitreal bevacizumab. Acta Ophthalmol Scand 2007; 85: 526-533.
31. Jonas JB, Libondi T, Ihloff AK, Harder B, Kreissig I, Schlichtenbrede F et al. Visual acuity change after intravitreal bevacizumab for exudative agerelated macular degeneration in relation to subfoveal membrane type. Acta Ophthalmol Scand 2007; 85: 563-565.
32. Aisenbrey S, Ziemssen F, Völker M, Gelisken F, Szurman P, Jaissle G et al. Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007; 247: 941-948.
33. Abraham-Marin ML, Cortes-Luna CF, Alvarez-Rivera G, Hernández- Rojas M, Quiroz-Mercado H, Morales-Cantón V. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: a pilot study. Graefes Arch Clin Exp Ophthalmol 2007; 245: 651-655.
34. Levy J, Shneck M, Rosen S, Klemperer I, Rand D, Weinstein O et al. Intravitreal bevacizumab (avastin) for subfoveal neovascular age-related macular degeneration. Int Ophthalmol 2008. [Epub ahead of print].